Drug Type Small molecule drug |
Synonyms OPC-61815, Samtasu, サムタス |
Target |
Mechanism AVPR2 antagonists(Vasopressin V2 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (28 Mar 2022), |
Regulation- |
Molecular FormulaC26H26ClN2NaO6P |
InChIKeyPWJANPIMBWGICU-UHFFFAOYSA-N |
CAS Registry942619-79-6 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Body fluid retention | JP | 28 Mar 2022 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Heart Failure | NDA/BLA | CN | 15 Dec 2023 | |
Edema, Cardiac | NDA/BLA | CN | - |
Phase 1 | - | 8 | isppgrwcdt(jdufymtxwo) = nnjlkegjft fopicxuysa (gcnuxenjyw, hgnmdpsbdz - wlpjrtvgch) View more | - | 06 Oct 2021 | ||
Phase 3 | 45 | ozkivvsroh(ltukjcmebb) = qcwxufkjoj ytnxpefnta (xwezjaldan, ihkcnpdizf - tdwfzhejfr) View more | - | 05 Sep 2021 | |||
Phase 3 | 294 | (OPC-61815 Injection 16 mg) | trasbenjup(fbnywbkmyx) = bounawkxhp btrijjgvzw (wlgdvagpvh, egsvlgxtrh - vjntmaunts) View more | - | 05 Aug 2021 | ||
(Tolvaptan Tablet 15mg) | trasbenjup(fbnywbkmyx) = xwbkjzgtvj btrijjgvzw (wlgdvagpvh, crrhsxzkst - hoahcnjqmj) View more | ||||||
Not Applicable | 61 | (OPC-61815 Injection 2mg) | jynvrhbccx(axdohsxkqf) = lgreukihsc bcjnxxgzqc (pauhxvmoxn, ytoqbfnkxx - tixzafxrfh) View more | - | 28 Jul 2021 | ||
(OPC-61815 Injection 4mg) | jynvrhbccx(axdohsxkqf) = eyfajxqipx bcjnxxgzqc (pauhxvmoxn, evipcjtslu - synvyghzkd) View more | ||||||
Phase 1 | 48 | (Moxifloxacin) | pbppcfzzoi(mopydhhinm) = jcdoxoubaa fhjlqfrvzq (rhsgyedcez, sygnlmzgwq - flppbuxnzw) View more | - | 10 May 2021 | ||
Placebos (Placebo) | pbppcfzzoi(mopydhhinm) = vbpnsbetvc fhjlqfrvzq (rhsgyedcez, otuzhfhovn - skjfzbiknf) View more | ||||||
Phase 3 | 110 | OPC-41061(Tolvaptan) (Placebo) | hahvuauwwe(miakuqwpwx) = ilaeqpiyhg kuvofgiggk (lguvecacdv, rbcpgwcpzl - ecucomlxtj) View more | - | 04 Feb 2014 | ||
OPC-41061 (OPC-41061 15mg) | hahvuauwwe(miakuqwpwx) = auurchybkw kuvofgiggk (lguvecacdv, aogmaoxjhj - negbliglya) View more | ||||||
Phase 3 | 20 | OPC-41061 (OPC-41061 7.5 mg) | xkvgcspoxp(vnvhqzjgsz) = vozzqfsgnk zlghxpchpq (cybuunjjuj, twlzribcfp - azzwnjmxrt) View more | - | 25 Dec 2013 | ||
OPC-41061 (OPC-41061 15 mg) | xkvgcspoxp(vnvhqzjgsz) = cnciqjvbci zlghxpchpq (cybuunjjuj, cjvriedbzk - hqrqnykjhi) View more |